Sun-Novo(SH:688621) Sou Hu Cai Jing·2025-08-22 22:45Group 1 - Chengdu Nuoheshenghong Biopharmaceutical Co., Ltd. applied for a "Type II meeting" on August 23, which is currently in "processing" status [1] - Type II meetings are held within 60 days after application and focus on critical issues during drug development, including pre-clinical trial meetings and pre-market application meetings [1] - The company was established in 2021, located in Chengdu, and primarily engages in the pharmaceutical manufacturing industry with a registered capital of 50 million RMB and paid-in capital of 3 million RMB [1] Group 2 - Chengdu Nuoheshenghong Biopharmaceutical Co., Ltd. holds 2 administrative licenses according to data analysis [2] - The company is wholly owned by Beijing Sunshine Nuohesheng Pharmaceutical Research Co., Ltd. [2]